These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 19369682)

  • 21. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment.
    Vakil E; Tefferi A
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
    Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
    Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
    Tefferi A; Levine RL; Kantarjian H
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloproliferative neoplasms: new translational therapies.
    Mascarenhas J; Hoffman R
    Mt Sinai J Med; 2010; 77(6):667-83. PubMed ID: 21105128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
    Agarwal MB
    J Assoc Physicians India; 2007 Jul; 55():507-10. PubMed ID: 17907502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular diagnosis of myeloproliferative neoplasms.
    Patnaik MM; Tefferi A
    Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
    Tefferi A
    Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
    Tefferi A
    Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K; Bock O; Kreipe H
    Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Jak-2 positive myeloproliferative neoplasms.
    Muxí PJ; Oliver AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
    Bojko P; Abenhardt W; Schnittger S; Haferlach T
    Onkologie; 2009 Apr; 32(4):191-5. PubMed ID: 19372714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
    Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
    J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic myeloproliferative disorders.
    Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
    Ohyashiki JH
    Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.